50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
Comcast is an Asset Bonanza Priced Cheap
Is the Market Overreacting with Shopify Stock?
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
British pound plunges to new low as tax cuts spark concern
US stocks slip deeper into a slump as recession fears grow
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
Comcast is an Asset Bonanza Priced Cheap
Is the Market Overreacting with Shopify Stock?
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
British pound plunges to new low as tax cuts spark concern
US stocks slip deeper into a slump as recession fears grow
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
Comcast is an Asset Bonanza Priced Cheap
Is the Market Overreacting with Shopify Stock?
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
British pound plunges to new low as tax cuts spark concern
US stocks slip deeper into a slump as recession fears grow
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
Comcast is an Asset Bonanza Priced Cheap
Is the Market Overreacting with Shopify Stock?
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green." (Ad)
British pound plunges to new low as tax cuts spark concern
US stocks slip deeper into a slump as recession fears grow
NASDAQ:ADVM

Adverum Biotechnologies - ADVM Stock Forecast, Price & News

$0.92
-0.04 (-4.16%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.91
$1.00
50-Day Range
$0.92
$1.74
52-Week Range
$0.80
$2.52
Volume
383,445 shs
Average Volume
1.09 million shs
Market Capitalization
$90.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

Adverum Biotechnologies MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
253.1% Upside
$3.25 Price Target
Short Interest
Healthy
2.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
0.59mentions of Adverum Biotechnologies in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$48,529 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.50) to ($1.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

136th out of 1,069 stocks

Biological Products, Except Diagnostic Industry

20th out of 171 stocks

ADVM stock logo

About Adverum Biotechnologies (NASDAQ:ADVM) Stock

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Receive ADVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

ADVM Stock News Headlines

See More Headlines
Receive ADVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

ADVM Company Calendar

Last Earnings
8/11/2022
Today
9/27/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADVM
Employees
188
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.25
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+253.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-145,540,000.00
Pretax Margin
-1,940.53%

Debt

Sales & Book Value

Annual Sales
$7.50 million
Book Value
$3.22 per share

Miscellaneous

Free Float
95,511,000
Market Cap
$90.91 million
Optionable
Optionable
Beta
1.14

Key Executives

  • Dr. Laurent  FischerDr. Laurent Fischer (Age 58)
    Pres, CEO & Director
    Comp: $921.08k
  • Mr. Kishor Peter Soparkar J.D. (Age 51)
    Chief Operating Officer
    Comp: $622.55k
  • Dr. Brigit Riley Ph.D. (Age 44)
    Chief Scientific Officer
    Comp: $816.08k
  • Mr. John W. Rakow J.D. (Age 65)
    Sr. VP, Gen. Counsel & Acting CFO
  • Ms. Nancy E. Pecota (Age 62)
    Principal Accounting Officer
  • Mr. Heikki Jouttijarvi
    Sr. VP & Head of Technical Operations
  • Ms. Dena House
    Sr. VP of HR, Organizational Devel. & Learning
  • Ms. Carla Fiankan
    Sr. VP of Regulatory Affairs
  • Dr. Jim Wang Ph.D.
    Chief Regulatory Officer
  • Mr. Michael Steel
    Sr. VP of Quality













ADVM Stock - Frequently Asked Questions

Should I buy or sell Adverum Biotechnologies stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADVM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADVM, but not buy additional shares or sell existing shares.
View ADVM analyst ratings
or view top-rated stocks.

What is Adverum Biotechnologies' stock price forecast for 2022?

3 brokers have issued 12-month target prices for Adverum Biotechnologies' stock. Their ADVM share price forecasts range from $2.50 to $4.00. On average, they expect the company's share price to reach $3.25 in the next twelve months. This suggests a possible upside of 253.1% from the stock's current price.
View analysts price targets for ADVM
or view top-rated stocks among Wall Street analysts.

How have ADVM shares performed in 2022?

Adverum Biotechnologies' stock was trading at $1.76 at the beginning of the year. Since then, ADVM stock has decreased by 47.7% and is now trading at $0.9204.
View the best growth stocks for 2022 here
.

When is Adverum Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ADVM earnings forecast
.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) posted its quarterly earnings results on Thursday, August, 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.06.

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a number of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (1.65%), Renaissance Technologies LLC (1.11%), Millennium Management LLC (1.05%), Assenagon Asset Management S.A. (0.95%), Monaco Asset Management SAM (0.45%) and State Street Corp (0.29%). Insiders that own company stock include Dawn Svoronos, James Paul Scopa, Julie Clark, Laurent Fischer, Leone D Patterson, Mehdi Gasmi, Patrick Machado, Peter Soparkar, Richard Beckman, Rupert D'souza and Setareh Seyedkazemi.
View institutional ownership trends
.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $0.92.

How much money does Adverum Biotechnologies make?

Adverum Biotechnologies (NASDAQ:ADVM) has a market capitalization of $90.91 million and generates $7.50 million in revenue each year. The biotechnology company earns $-145,540,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does Adverum Biotechnologies have?

The company employs 188 workers across the globe.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.adverum.com. The biotechnology company can be reached via phone at (650) 656-9323, via email at mlacy@adverum.com, or via fax at 650-329-8151.

This page (NASDAQ:ADVM) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.